CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

Abstract Background Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized therapeutic drug, came out in 1970 and is still the only first-line treatment for ACC in spite of serious adverse re...

Full description

Bibliographic Details
Main Authors: Liwen Ren, Yihui Yang, Wan Li, Xiangjin Zheng, Jinyi Liu, Sha Li, Hong Yang, Yizhi Zhang, Binbin Ge, Sen Zhang, Weiqi Fu, Dexin Dong, Guanhua Du, Jinhua Wang
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Translational Medicine
Subjects:
Adrenocortical carcinoma
CDK1
Cucurbitacin E
Mitotane
EMT
Epithelial-mesenchymal transition
Online Access:https://doi.org/10.1186/s12967-022-03641-y

Internet

https://doi.org/10.1186/s12967-022-03641-y

Similar Items